Table 3 Adverse events notified in the 30 patients

From: Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

Adverse events All grades no.a (%) Grade 3 or 4 no.a (%)
Hematologic toxicity 11 (37) 6 (20)
Anemia 1 (3) 0
Neutropenia 10 (33) 5 (17)
Thrombocytopenia 6 (20) 3 (10)
Nonhematologic toxicity 15 (50) 2 (7)
Infection 5 (17) 1 (3)
Skin rash 4 (13) 0
Nausea 4 (13) 0
Vomiting 3 (10) 0
Liver transaminase elevation 2 (7) 1 (3)
Diarrhea 1 (3) 0
Edema 1 (3) 0
Headache 1 (3) 0
  1. aNumber of patients who experienced hematological or nonhematological toxicities.
  2. Some patients experienced more than one side effects.
Back to article page